{"commentary":{"count":3,"free_build_floor":8,"listing_floor":3,"by_channel":{"x_thread":3},"note":"Indexed podcasts, YouTube videos and X posts that name this trial. A report screens them, searches for more and cites what clinicians said when it is built."},"free_build":{"available":false},"name":"FLAME","nct_id":"NCT04769388","offer":{"currency":"USD","how":"Order at https://www.erudio.com/contact?report=flame-nct04769388. The price is fixed at order. We build the report after the order and deliver it when it passes our checks; if it cannot be built to our standard, nothing is charged.","price_usd":750,"size":"focused","size_rule":"Focused: 1–12 commentary sources"},"registry":{"acronym":"FLAME","arms":[{"description":"Osimertinib 80 mg in combination with pemetrexed (500 mg/m2) plus carboplatin (AUC5) on Day 1 of 21day cycles (every 3 weeks) for up to 6 cycles, followed by Osimertinib daily with pemetrexed maintenance (500 mg/m2) every 3 weeks.","label":"Osimertinib 80 mg QD and platinum-based chemotherapy","type":"EXPERIMENTAL"},{"description":"All patients randomized into this will only receive Osimertinib 80mg.","label":"Osimertinib 80mg QD","type":"ACTIVE_COMPARATOR"}],"collaborators":["Cancer Institute and Hospital, Chinese Academy of Medical Sciences"],"completion_date":{"date":"2026-01-24","type":"ACTUAL"},"conditions":["Non Small Cell Lung Cancer"],"enrollment":{"count":80,"type":"ACTUAL"},"has_results":false,"interventions":[{"name":"Osimertinib","type":"DRUG"},{"name":"Pemetrexed/Carboplatin","type":"DRUG"}],"last_update":"2026-08-12","lead_sponsor":"Beijing Cancer Prevention & Treatment Society","official_title":"The Efficacy and Safety of Osimertinib Plus Carboplatin and Pemetrexed Versus Osimertinib Monotherapy in Metastatic EGFRm NSCLC Patients With EGFRm Persistence in ctDNA at 3 Weeks After 1L Osimertinib: A Multicenter, Randomized Controlled Study","overall_status":"COMPLETED","phases":["PHASE2"],"primary_completion_date":{"date":"2026-01-24","type":"ACTUAL"},"primary_outcomes":[{"measure":"Progression free survival","timeFrame":"The primary analysis of Progression-free survival (PFS) based on investigator assessment will occur when PFS maturity is observed at approximately 30 months after the first patient is randomized."}],"references":[],"start_date":{"date":"2021-12-28","type":"ACTUAL"},"study_type":"INTERVENTIONAL","title":"Osimertinib Plus Chemotherapy vs Osimertinib in EGFRm NSCLC With Persistence Week-3 ctDNA EGFRm After 1L Osimertinib","url":"https://clinicaltrials.gov/study/NCT04769388"},"report":null,"schema_id":"erudio.trial_listing","schema_version":"2.0","state":"listed","state_text":"No report yet. It can be ordered.","url":"https://www.erudio.com/trials/flame-nct04769388"}